The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe t...

Descripción completa

Detalles Bibliográficos
Autores principales: Condit, Richard C, Kim, Denny, Robertson, James S., Excler, Jean-Louis, Gurwith, Marc, Monath, Thomas P., Pavlakis, George, Fast, Patricia E., Smith, Jonathan, Smith, Emily R., Chen, Robert T., Kochhar, Sonali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474958/
https://www.ncbi.nlm.nih.gov/pubmed/32907759
http://dx.doi.org/10.1016/j.vaccine.2020.08.009
Descripción
Sumario:Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines.

Ejemplares similares